Key Highlights
- Revenue was USD 8.00 million against an estimate of USD 12.00 million.
- Net loss per share was USD 10.19 against an estimate of a USD 2.40 loss.
- Net loss was USD 144.46 million, compared with USD 18.74 million.
- Cash and cash equivalents were USD 135.35 million at September 30, 2026.
Jasper Therapeutics (NASDAQ:JSPR) reported Revenue of USD 8.00 million for the third quarter of 2026, with no revenue in the third quarter of 2025, against an estimate of USD 12.00 million. The net loss was USD 144.46 million, compared with USD 18.74 million, and the net loss per share attributable to common stockholders was USD 10.19, compared with USD 32.08, against an estimate of a USD 2.40 loss.
On July 16, 2026, the company acquired Kira Pharmaceuticals, and the results of Kira are included from the Acquisition date.
Costs and Operating Loss
Cost of drug supplies and compounds was USD 7.99 million. Research and Development expense was USD 8.33 million, compared with USD 14.39 million, and general and administrative expense was USD 6.36 million, compared with USD 4.78 million. Acquired in-process research and development expense was USD 129.49 million, with none in the prior-year quarter.
Total costs and expenses were USD 152.17 million, compared with USD 19.17 million, and the loss from operations was USD 144.17 million, compared with USD 19.17 million. Interest income was USD 1.00 million, compared with USD 0.34 million.
Nine-Month Results
For the nine months ended September 30, 2026, revenue was USD 8.00 million, and the net loss was USD 148.39 million, compared with USD 66.70 million. The net loss per share attributable to common stockholders was USD 14.31, compared with USD 125.30. Research and development expense was USD 19.28 million, compared with USD 51.74 million, and general and administrative expense was USD 15.57 million, compared with USD 16.30 million. The change in Fair Value of the Warrant Liability was USD 12.38 million.
Balance Sheet
Cash and cash equivalents were USD 135.35 million at September 30, 2026, compared with USD 28.69 million at December 31, 2025. Accounts Receivable were USD 8.00 million, and total Assets were USD 147.42 million, compared with USD 35.78 million. Total liabilities were USD 20.89 million, compared with USD 31.63 million, and the warrant liability was USD 3.78 million, compared with USD 16.16 million. The filing states that contingent value rights entitle holders to receive, on a pro rata basis, up to USD 30.0 million upon achievement of the applicable milestone, with an initial fair value of USD 1.9 million.
The filing describes the company's Going Concern evaluation under ASC Topic 205-40. It states that the company incurred net losses of USD 144.5 million and USD 148.4 million for the three and nine months ended September 30, 2026, had negative cash flows from operations of USD 27.0 million for the nine months, compared with USD 55.3 million, and had an accumulated Deficit of USD 465.1 million.
Each share of non-voting redeemable convertible preferred stock is automatically convertible into 2.03 shares of voting common stock following stockholder approval, and 9,555,390 shares were issued. Starting in July 2025, the company implemented a corporate reorganization and other cost reduction measures to extend its cash runway. Weighted-average shares used in computing net loss per share were 1,075,259 for the quarter, compared with 584,056.
Jasper Therapeutics Q3 2026 Earnings: Key Takeaways
Jasper Therapeutics reported third quarter 2026 revenue of USD 8.00 million and a net loss of USD 144.46 million. Cash and cash equivalents were USD 135.35 million at September 30, 2026.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...